Akebia Therapeutics, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On 2026-10-21, Akebia Therapeutics received notice of delisting or failure to satisfy continued listing rules/standards from its exchange. The filing does not specify which exchange, which specific rule was violated, the dollar amount involved, or any remediation timeline. This is a bare notification of a delisting notice without substantive detail on the trigger or consequences.
Why this rating
Delisting threat is material to a $946M public company—directly threatens market access, liquidity, and shareholder value. Exact cause and remedy timeline unknown, limiting precision.
Extracted items
Price action (we called it negative)
before filing · preread $0.57 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.